DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation-Reference-Cited by-同舟云学术

DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation

Published:2022-05 Issue: Volume:345 Page:75-90
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Leung Ada W.Y.,Chen Kent T.J.,Ryan Gemma M.,Anantha Malathi,Wretham Nicole,Nosrati Zeynab,Heroux Devon,Wang Linchuan,Chow Norman,Dai Zhongye,Bally Marcel B.

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference71 articles.

1. Discovery of CX-5461, the first direct and selective inhibitor of RNA polymerase I, for Cancer therapeutics;Haddach;ACS Med. Chem. Lett.,2012

2. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth;Drygin;Cancer Res.,2011

3. Ribosome biogenesis in cancer: new players and therapeutic avenues;Pelletier;Nat. Rev. Cancer,2018

4. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling;Quin;Oncotarget,2016

5. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML;Lancet;Blood,2014

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liposomal Formulations of Metallodrugs for Cancer Therapy;International Journal of Molecular Sciences;2024-08-28

2. Accumulation of liposomes in metastatic tumor sites is not necessary for anti-cancer drug efficacy;Journal of Translational Medicine;2024-07-03

3. A nano-platform combats the “attack” and “defense” of cytoskeleton to block cascading tumor metastasis;Journal of Controlled Release;2024-03

4. Liver-Specific Ionizable Lipid Nanoparticles Mediated Efficient RNA Interference to Clear “Bad Cholesterol”;International Journal of Nanomedicine;2023-12

5. Liposomal form of 2-alkylthioimidazolone-based copper complexes for combined cancer therapy;Nanomedicine;2023-12